SLC16A1 and glioblastoma: Specifically, patients with GBM expressed significantly higher levels of the MCT1 messenger in the brain than did patients with oligodendrocytoma (p < 0.0001) and astrocytoma (p < 0.0001) or healthy subjects (p < 0.0001) (Figure 6A).